{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007415","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.456141+00:00","generated_at":"2026-05-16T18:39:17.819232+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aptose to be acquired by Hanmi Pharmaceutical at C$2.41/share, 28% premium to 30-day VWAP","bullets":["Hanmi already owns 19.93% and provided >US$30M in debt facilities over 18 months.","Transaction requires approval of 2/3 of votes, plus minority approval; special meeting by Jan 16, 2026.","Formal valuation by Locust Walk: fair market value range of C$1.00 to C$5.23 per share.","Aptose will be delisted from TSX and cease Canadian reporting obligations after closing.","Officers and directors have entered voting support agreements in favor of the arrangement."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007415","json":"https://secwatch.observer/filing/0001171843-25-007415.json","markdown":"https://secwatch.observer/filing/0001171843-25-007415.md","text":"https://secwatch.observer/filing/0001171843-25-007415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325007415/0001171843-25-007415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325007415/f8k_111925.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:39:17.819232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}